|
At Lupin, we have developed the requisite manufacturing muscle to support our flight to higher levels. With consistent and continued investments in augmenting our manufacturing capacities, we have ensured that our capabilities are completely attuned to our growth aspirations. Our state-of-the-art manufacturing plants add to our ability to deliver quality and scale, having successfully integrated our capabilities and capacities to deliver a wide product portfolio that caters to the varied needs of diverse markets. Committed to quality, safety and the environment, most of our manufacturing facilities have been inspected and approved by the US FDA and UK MHRA, WHO, Australian TGA and Japan’s MHLW. Formulations make up 81% of our overall revenue composition.
Our Formulation Facilities:
|
Aurangabad
|
Jammu
|
|
Mandideep |
Indore
|
|
Goa |
|
Our API Facilities:
|
Ankleshwar
|
Mandideep
|
|
Tarapur |
Vadodara
|
 |
|
Key Products: APIs and Intermediates
Approved by:
WHO (Geneva)
|
|
Ankleshwar, Gujarat, India |
|
Top |
| |
|
|
|
| |
|
|
 |
|
Key Products: APIs and
Intermediates
Approved by:US FDA
WHO
|
|
Tarapur, Maharashtra, India |
|
Top |
| |
|
|
|
| |
|
|
 |
|
Key Products: APIs and Formulations
Approved by:
WHO
US FDA
UK MHRA |
|
|
|
Mandideep, Madhya Pradesh, India |
|
Top |
| |
|
|
|
| |
|
|
 |
|
Key Products: Formulations
Approved by:
WHO (Geneva)
|
|
Aurangabad, Maharashtra, India |
|
Top |
| |
|
|
|
| |
|
|
 |
|
Key Products: Formulations
Approved by:US FDA
UK MHRA
|
| |
|
| |
|
|
Goa, India |
|
Top |
|
|
|
|
|
|
|
|
|
 |
|
Key Products: Formulations
|
|
|
| |
|
| |
|
| |
|
| |
|
|
Jammu, Jammu & Kashmir, India |
|
Top |
|
|
|
|
|
|
|
|
|
 |
|
Key Products: Formulations
Approved by:
(In the pipeline)
|
| |
|
| |
|
| |
|
|
Indore, Madhya Pradesh, India |
|
Top |
|
|
|
|
|
|
|
|
|
 |
|
Key Products: Formulations
Approved by:
MOH (Japan)
|
|
|
|
|
|
Kyowa, Japan |
|
Top |
|
|
